The scale of the phenomenon is striking. In a landmark cross-biobank epidemiological study encompassing 883,574 female participants from eight biobanks across Europe and East Asia, 105,286 women—11.9 percent—carried detectable LOX in their peripheral blood DNA, and 5,475 women carried expanded LOX, defined as the mutation present in more than 5 percent of circulating leukocytes. Prevalence rises continuously with age: in the Mass General Brigham Biobank, detectable LOX increases linearly from 3.5 percent in women under 40 to 33.5 percent in women aged 80 to 85, before dropping to 26.3 percent in women 85 and older, suggesting that the burden may reach an upper limit beyond which the mutation becomes incompatible with life. Earlier cytogenetic work using fluorescence in situ hybridization found LOX in roughly 1.7 percent of lymphocytes from young women but in approximately 22 percent of centenarian women, underscoring the age gradient across the entire human lifespan.

LOX is not a random event. Female cells carry two X chromosomes that differ fundamentally in their epigenetic state: one remains transcriptionally active, while the other is condensed into the inactive X, or Barr body, silenced by the long non-coding RNA XIST during early embryogenesis. Mathematical modeling of LOX profiles from UK Biobank participants has revealed that losing one X chromosome is far more plausible than losing the other, with two distinct LOX events occurring at rates varying by a factor of 140. Three non-exclusive models have been proposed to explain this bias. The first holds that the inactive X is preferentially lost, because retaining the active X maintains adequate gene dosage for cell survival. The second posits that one parentally derived X—either maternal or paternal—is preferentially affected regardless of its activation status. The third, building on both, suggests that the inactive X derived from one specific parent is the most vulnerable target. Single-cell analyses have recently provided evidence that the inactive X is always the chromosome affected by LOX, though the population-genetic modeling paradoxically predicts that the rate of active X loss is more than 70-fold higher than the rate of inactive X loss per year, indicating that both states are substantially impacted at the mutation stage.

What makes the X chromosome, particularly the inactive copy, so prone to vanishing? Cell division is the primary source of chromosome loss, and cytogenetic analysis of cultured lymphocytes from a healthy 62-year-old woman found that the X chromosome represented one-quarter of all lagging chromosomes—six times more often than would be expected by chance. The inactive X carries several intrinsic liabilities. It preferentially undergoes premature centromere division, the precocious loss of centromeric cohesion that drives nondisjunction, likely because XIST RNA actively repels cohesin complexes from the chromosome. It localizes to the nuclear periphery, where chromosomes take longer to align at metaphase and are more likely to be missegregated and incorporated into micronuclei. It replicates late in S phase and accumulates a disproportionately higher mutational load, driven in part by preferential de novo LINE-1 retrotransposon insertions originating from the active X and autosomes. DNA repair is also less efficient in the inactive X than in the active X, and the structural and epigenetic stability of the active X is rigorously safeguarded by master factors such as the deacetylase SIRT7.

A particularly elegant recent discovery has added a structural dimension to this vulnerability. The inactive X is partitioned into two extremely large intervals called superdomains, separated by a boundary containing the microsatellite repeat DXZ4, and it carries superloops—large chromatin loops anchored at DXZ4 that also interact with two other X-linked microsatellite repeats, FIRRE and ICCE. Copy number variations of ICCE and DXZ4 have been found to strongly associate with LOX levels across both UK Biobank and All of Us cohorts. Women with longer arrays of ICCE or DXZ4 show increased LOX in cis, and the effects of these two repeats are additive, contributing to a fourfold range in the likelihood that different X chromosomes will be lost. Two variants within the DXZ4 array that appear to reduce CTCF and YY1 binding disrupt the effect of DXZ4 on LOX, suggesting that increased CTCF and YY1 binding at longer DXZ4 arrays reduces the segregation fidelity of the inactive X. While this hub of repeats is dispensable for the establishment of X chromosome inactivation, it appears essential for the mitotic stability of the silenced chromosome.

Beyond mutation, LOX clones must expand to become clinically relevant, and this expansion is governed by a competitive landscape that researchers have begun to describe as X chromosome-linked competition. The maternal and paternal X chromosomes in any given woman differ by at least 150 non-synonymous coding variants and thousands of non-coding variants, creating fitness differences between clones that retain different parental copies. Three mutually non-exclusive competition scenarios operate in LOX carriers: competition between 45,X cells retaining either the maternal or paternal X, competition between 45,X cells retaining either the active or inactive X, and competition between 45,X and normal 46,XX cells. Evidence from allelic shift analyses has shown that 44 independent X-linked alleles and 59 coding variants exhibit significant shifts in LOX individuals, suggesting they confer differential selective advantages. Simulation work has revealed that loss of the inactive X drives a twofold higher fitness effect compared with loss of the active X, with growth rates of 15.7 percent and 7.3 percent per year respectively, and longitudinal data from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening study indicate that the average population expansion rate of LOX is 0.3 percent per year of age.

The clinical associations of LOX are diverse and increasingly well documented. Detectable LOX is separately associated with increased risk of leukemia overall, acute myeloid leukemia, and chronic lymphoid leukemia by 1.7-fold, 1.9-fold, and 3.3-fold respectively, and expanded LOX confers even greater risks—6.3-fold for leukemia overall, 10.6-fold for acute myeloid leukemia, and 14.7-fold for chronic lymphoid leukemia. These associations with expanded LOX and leukemia risk in UK Biobank persisted even after removing individuals with other clonal hematopoiesis events, indicating that LOX is independently associated with leukemia risk. Beyond hematological malignancy, expanded LOX is associated with heightened risk of systemic sclerosis in Japanese cohorts and with roughly threefold increased risk of Graves’ disease and rheumatoid arthritis in elderly participants of cross-biobank studies. LOX is also associated with increased risk of bacterial pneumonia, a 3.9-fold increase in arterial embolism and thrombosis in the Million Veteran Program, and significantly increased rates of suicide in a large retrospective Japanese study. Notably, women with LOX present in at least 0.87 percent of cells have a 2.16-fold lower likelihood of natural conception, suggesting that even non-expanded LOX may carry pathogenic weight.

The functional consequences of losing an entire chromosome are profound and operate through multiple interconnected mechanisms. LOX entails deletion of hundreds of dosage-sensitive genes, including those in the pseudoautosomal regions and X-Y gametologs that are normally expressed from both copies in both sexes. In response, mammalian stem cells upregulate the remaining active X through a process called X chromosome upregulation, compensating for the dosage imbalance, though this compensation is clearly insufficient to fully rescue the monosomic state. More surprisingly, the historically dismissed inactive X is now recognized as a functionally active chromosome that modulates the expression of autosomal genes in trans. Among four cell types of hematopoietic lineage, the inactive X elicits cell-type-specific responses on autosomal and active X gene expression, and 45,X human induced pluripotent stem cells derived from 46,XX fibroblasts show dysregulated expression of several autosomal genes with regulatory functions. The inactive X also serves as a female-specific buffering mechanism against recessive mutations and as a reservoir dynamically used along neural differentiation, and it tends to become partially reactivated with aging, overexpressing immunity-related genes that increase susceptibility to autoimmunity while simultaneously counteracting age-related cognitive decline in mouse models.

Perhaps the most tantalizing question is whether LOX is a cause or a consequence of biological aging. Preliminary results have shown that subjects with detectable LOX display a 1.82-fold acceleration in DNA methylation-based epigenetic clocks, suggesting LOX is a driver of epigenetic aging. One-directional Mendelian randomization did not suggest a causal relationship between telomere attrition and LOX; instead, telomere length reduction in LOX individuals may be a marker of past clonal growth and expansion. As telomere erosion is itself a driver of aging, reduced telomere length in LOX clones could lead to further genomic instability and the acquisition of additional aging hallmarks. Together, these findings point toward a self-reinforcing loop in which aging promotes the acquisition and expansion of LOX through mechanisms such as inflammaging and declining p53 function, while LOX in turn accelerates biological aging through telomere shortening and epigenetic clock acceleration. Whether modulating LOX burden can be exploited to prevent or mitigate disease in women remains an open question, but the field is moving rapidly from observational studies toward a data-rich discipline with the potential to reshape our understanding of sex differences in aging and age-related disease.

Subject of Research: Loss of the X chromosome in aging women's blood cells as an exemplar of genome aging

Article Title: Genome Aging in Women: Hematopoietic Loss of X Chromosome as An Exemplar

Article References: Guo, X., & Dai, X. (2026). Genome Aging in Women: Hematopoietic Loss of X Chromosome as An Exemplar. Aging Cell, 25(11), Article e70778. https://doi.org/10.1111/acel.70778

Image Credits: AI Generated

DOI: 10.1111/acel.70778

Keywords: loss of X chromosome, genome aging, clonal hematopoiesis, mosaic chromosomal alterations, inactive X chromosome, X chromosome inactivation, cell competition, leukemia risk, autoimmunity, aging women, UK Biobank, somatic mutation

The research centers on a long-standing question in cancer biology: how does p53, the most frequently inactivated tumor suppressor in human cancers, actually suppress tumorigenesis? Decades of work in mammalian cells have catalogued dozens of p53-regulated genes, but the sheer complexity of mammalian genomes has made it difficult to assign specific tumor-suppressing functions to individual downstream effectors. Model organisms with simpler gene regulatory landscapes can help. In the fruit fly Drosophila melanogaster, the authors note, the primary transcriptional target of p53 is the gene encoding Xrp1, a transcription factor of the bZip AT-hook family. That simplicity makes the fly an unusually clean system for asking what a single p53 target gene actually accomplishes when the genome comes under attack.

The study’s first major finding is that Xrp1 is not merely one p53 target among many—it is a genuine mediator of p53’s functions in the DNA damage response, often abbreviated DDR. When the authors examined flies with reduced Xrp1 function, they found defects in p53-dependent gene transcription following DNA damage, indicating that Xrp1 feeds back into the transcriptional program that p53 initiates. They also found that Xrp1 contributes to p53-dependent apoptosis, the programmed cell death that eliminates severely damaged cells before they can propagate mutations. In other words, Xrp1 sits downstream of p53 and helps execute two of p53’s most important protective outputs: amplifying the damage-response transcriptional program and triggering the destruction of compromised cells.

But the story does not end with p53. Previous work had established a second, p53-independent role for Xrp1 in a phenomenon known as cell competition. Cell competition is a form of intercellular comparison in which cells that are less fit—because of mutations, defects in protein synthesis, or other suboptimal states—are actively eliminated by their more fit neighbors. Crucially, cell competition can remove cells whose genomes have been altered by DNA damage and subsequent repair, even after the acute damage response has subsided. This makes it a plausible second line of defense: where the DDR fails to fully restore a normal genome, competition may cull the imperfect cells from the tissue altogether.

To understand how Xrp1 is recruited into this second pathway, the authors turned to a protein called RpS12. During cell competition, Xrp1 is induced by RpS12, which acts as a sensor of defective ribosome biogenesis—the process by which cells build their protein-making machinery. Cells with compromised ribosome production or function trigger RpS12-dependent signaling, which in turn elevates Xrp1, marking them for elimination by their neighbors. This places Xrp1 at the hub of two distinct regulatory circuits: one routed through p53 in response to DNA strand breaks, and another routed through RpS12 in response to defects in the cellular protein synthesis apparatus.

The temporal relationship between these two circuits emerged as one of the most striking aspects of the study. The researchers irradiated developing fly tissues—specifically imaginal discs, the larval precursors of adult structures—and tracked Xrp1’s behavior over time. They found that the p53-independent, RpS12-dependent function of Xrp1 began only as the acute DNA damage response was coming to an end. In other words, the two pathways do not operate simultaneously; they are staged. First, the p53-dependent DDR confronts the damage directly, activating repair genes and apoptosis. Then, as that acute phase winds down, the RpS12-dependent competitive mechanism takes over, targeting any cells that remain abnormal.

Even more revealing was what happened when the authors reduced p53 function in irradiated tissues. Under these conditions, the RpS12-dependent Xrp1 response became even more prominent, suggesting that the competitive pathway can compensate, at least partially, when the canonical DDR is weakened. But the compensation came at a cost. Inhibition of p53 resulted in the persistence of DNA damage after irradiation, which the authors detected through the accumulation of γH2Av, the fly equivalent of γH2AX, a phosphorylated histone variant widely used as a marker for DNA double-strand breaks. Persistent γH2Av signaling indicated that breaks that should have been repaired—or the cells carrying them—were lingering in the tissue.

Taken together, these results support a model in which Xrp1 limits the accumulation of abnormal cells arising from genotoxicity through two complementary mechanisms. In the acute phase, acting as a p53 effector, it promotes the transcriptional response to damage and the apoptotic removal of heavily injured cells. In the later phase, acting in an RpS12-dependent, p53-independent manner consistent with cell competition, it contributes to the elimination of cells in which DNA repair failed to restore a normal genome. The two mechanisms are not redundant so much as sequential and overlapping, with the competitive pathway becoming more prominent precisely when the DDR is compromised.

The evolutionary implications extend well beyond the fly. Both p53 and the core machinery of the DNA damage response are conserved from insects to mammals, and cell competition has been documented in mammalian tissues as well. If Xrp1-like mechanisms operate in vertebrates, the study suggests that the tumor-suppressing power of p53 may depend not only on the genes it directly controls but also on how those genes hand off responsibility to surveillance systems that operate on longer timescales. A cell that escapes p53-mediated apoptosis after irradiation or chemotherapy might still be vulnerable to competitive elimination—unless it also acquires mutations that disable the competition pathway, a possibility that could help explain why tumors so often exhibit defects in multiple quality-control systems simultaneously.

The work also carries practical resonance for cancer treatment. Many therapies, including radiation and several classes of chemotherapy, act by inflicting DNA damage on dividing cells, relying on the patient’s own DDR and tissue surveillance to finish the job. The finding that p53 inhibition allows DNA damage to persist in fly tissues—while simultaneously shifting the burden onto an RpS12-dependent competitive mechanism—illustrates how the genetic context of a cell shapes its fate after genotoxic insult. Understanding the handoff between the acute DDR and cell competition, and the central role that Xrp1 plays in both, may therefore illuminate not only how genomes are protected during normal development but also why some damaged cells survive, persist, and ultimately seed disease.

Subject of Research: The dual roles of the Drosophila protein Xrp1 in the DNA damage response and cell competition

Article Title: Dual contributions of Xrp1 to genome integrity through the DNA damage response and cell competition

Article References: Khan, C., Rusan, N. M., & Baker, N. E. (2026). Dual contributions of Xrp1 to genome integrity through the DNA damage response and cell competition. PLOS Genetics, 22(9), e1012309. https://doi.org/10.1371/journal.pgen.1012309

Image Credits: AI Generated

DOI: 10.1371/journal.pgen.1012309

Keywords: Xrp1, p53, DNA damage response, cell competition, Drosophila, RpS12, genome integrity, apoptosis, ribosome biogenesis, tumor suppression, gamma-H2Av, PLOS Genetics

The research team, led by Taiji Matsusaka of Tokai University School of Medicine, built a transgenic mouse platform designed to force podocytes back into the cell cycle on demand. The system exploits the Tet-On inducible expression technology, in which a tetracycline-responsive element drives transgene expression only when the antibiotic doxycycline is present. The authors microinjected a construct containing the Simian virus 40 large T antigen (SV40T) coding sequence, together with a lacZ reporter, into fertilized mouse eggs and established transgenic lines. SV40T is a viral oncoprotein best known for promoting cell-cycle entry by binding and functionally inactivating two key tumor suppressors, p53 and the retinoblastoma protein (Rb). Because it can push otherwise quiescent cells past the G1 restriction point, it is a standard tool for immortalizing podocytes in culture, making it a logical choice for attempts to stimulate division in vivo.

The transgenic line was crossed with Nphs2-rtTA mice, in which the reverse tetracycline transactivator is expressed specifically in podocytes under the podocin promoter. In double-transgenic offspring, doxycycline in the drinking water therefore triggered SV40T production exclusively in podocytes. The specificity was confirmed by immunostaining: after four to fourteen days of treatment, roughly twenty to thirty percent of podocytes per glomerular section expressed the viral antigen, while untreated animals and single-transgenic controls showed nothing. Critically, the forced cells did more than merely turn on the transgene. Between 9.3 and 17.7 percent of podocytes became positive for Ki67, a marker spanning late G1 through mitosis, incorporated bromodeoxyuridine to indicate DNA synthesis, expressed Aurora kinase B, and occasionally displayed mitotic figures. At the same time, p57Kip2, a cyclin-dependent kinase inhibitor that typifies the mature podocyte state, was downregulated in the SV40T-positive cells. The quiescent filter cells had, by every molecular criterion, re-entered the cell cycle.

In adult mice, however, this proliferative push came at a steep price. Cytokinesis frequently failed, leaving podocytes multinucleated or bearing enlarged nuclei. Within the first week of doxycycline exposure, kidney morphology was largely preserved apart from microvillous transformation of the podocytes, but the urinary albumin-to-creatinine ratio climbed dramatically, from control values near 0.02 to 15.76 by day seven and 40.27 by day fourteen. By two weeks, the slit diaphragm proteins nephrin and podocin were reduced and the injury marker desmin appeared in glomerular segments. After four or more weeks of continuous induction, every treated mouse developed focal segmental glomerulosclerosis of the usual type, complete with secondary tubulointerstitial damage in the most severely affected kidneys. Intriguingly, the damaged podocytes no longer expressed SV40T, apparently because podocyte injury extinguishes Nphs2-driven rtTA expression, an automatic brake on the system. Repeated short treatment cycles combined with the angiotensin receptor blocker losartan produced only a modest, marginal increase in podocyte counts, confirming that adult podocytes resist expansion even under carefully titrated conditions.

That failure redirected the strategy toward embryogenesis, a period when podocyte progenitors are naturally proliferative and the glomerulus has not yet been exposed to high filtration pressures. Pregnant dams carrying SV40T/rtTA embryos received doxycycline from embryonic day 14.5 until birth. The team also incorporated a third genetic element: Bcl2 knockout alleles. Homozygous Bcl2-deficient mice are a classical model of oligomeganephronia, a condition in which apoptosis of undifferentiated mesenchymal cells between embryonic days 13 and 16 drastically reduces nephron number, forcing the surviving glomeruli to enlarge compensatorily. This provided a natural test bed for whether extra podocytes could augment, or even drive, glomerular hypertrophy under strong physiological pressure.

The results at birth were striking. Newborn double-transgenic pups, on either Bcl2 background, carried markedly more podocytes than their littermate controls, with nearly all inner-cortical podocytes expressing SV40T and most of those positive for Ki67. On average, the number of WT1-positive podocytes per glomerulus rose by 54 percent. Importantly, these surplus cells had not simply dedifferentiated into a pathological mass: they retained robust expression of podocin, WT1, and podocalyxin, the molecular signature of committed podocytes, and they did not resemble the crescents seen in collapsing glomerulopathies. Yet the glomerular tuft area, measured by painstaking morphometry of all non-tangential glomeruli across entire kidney cross-sections, was not significantly larger than in controls. Even individual glomeruli loaded with excessive podocytes never exceeded the size of ordinary control glomeruli. The correlation between podocyte number and glomerular volume, so reliable in normal growth, had been decisively broken from the other direction.

Rather than integrating neatly into the filtration barrier, the extra podocytes misbehaved structurally. They formed multilayers instead of the normal monolayer, detached from the glomerular basement membrane, and scattered into Bowman’s space or even into tubular lumens. Double immunostaining showed that most cells remained mononuclear, with WT1-positive nuclei enclosed by podocalyxin, arguing against rampant failed division. Markers of DNA damage (gammaH2AX) and apoptosis (cleaved lamin A) appeared in only a small fraction of cells, averaging 0.26 and 0.39 per glomerulus respectively. The authors interpret this pattern as evidence that adhesive failure during mitotic rounding, rather than programmed cell death, is the dominant mechanism of loss. During mitosis, epithelial cells normally round up and transiently weaken integrin-mediated adhesion before reattaching; podocytes, with their intricate foot-process architecture and dependence on precise attachment to the basement membrane, appear exceptionally vulnerable to this structural upheaval.

The Bcl2-deficient experiments sharpened the conclusion. All Bcl2 knockout mice, regardless of transgene status, showed severe renal hypoplasia with few, enlarged glomeruli. In SV40T-expressing Bcl2-deficient pups, podocyte numbers rose as in the wild-type background, but many cells again detached from the glomerular basement membrane, and the tuft area was actually significantly smaller than in Bcl2-deficient littermates lacking the transgene. In other words, even when compensatory hypertrophy should have been pushing glomeruli to expand, the surplus, poorly anchored podocytes appeared to exert a squeezing effect that constrained tuft growth. Structural integration, not cell supply, proved to be the limiting factor.

Postnatal follow-up sealed the outcome. Among 26 pups analyzed at postnatal day 7, the previously excessive podocyte populations had vanished: podocyte number and tuft area in transgenic animals were indistinguishable from controls, and glomeruli containing more than thirty podocytes, common at birth, were no longer observed. The authors propose several non-exclusive explanations for this elimination. Podocytes may lack the stringent planar-division orientation control that keeps renal tubular epithelia in a monolayer, dooming misplaced daughters. Alternatively, a quality-control mechanism known as cell competition, in which fitter neighbors actively expunge less fit cells, may recognize SV40T-induced podocytes as losers and remove them, effectively imposing an occupancy-management system on the glomerular tuft.

The broader implication is a reframing of how glomerular size is set. Because the Nphs2 promoter only activates once podocytes have passed the S-shaped body stage, the study could not boost progenitor pools at earlier stages, and the authors conclude that glomerular size is likely determined at or before that point in nephrogenesis. Adding podocytes afterward, even during the permissive embryonic environment, cannot override the architectural constraints of the developing tuft. For regenerative medicine, the message is sobering but precise: future strategies to expand the podocyte population must either target earlier progenitor stages or solve the biophysical problems of division orientation and cell-matrix adhesion so that new cells can stably integrate into the filter. Simply forcing mature or nearly mature podocytes to cycle, whether by viral oncoproteins or other means, produces cells that the glomerulus cannot accommodate and ultimately discards.

Subject of Research: The effect of experimentally induced podocyte proliferation on glomerular size in mice

Article Title: Increase in podocyte number induced by SV40T antigen during the fetal stage does not expand glomerular size in mice

Article References: Matsusaka, T., Ichimura, K., Miyaki, T., & Koizumi, M. (2026). Increase in podocyte number induced by SV40T antigen during the fetal stage does not expand glomerular size in mice. Physiological Reports, 14(19), Article e71114. https://doi.org/10.14814/phy2.71114

Image Credits: AI Generated

DOI: 10.14814/phy2.71114

Keywords: podocytes, glomerulus, SV40 large T antigen, kidney development, Tet-On system, focal segmental glomerulosclerosis, Bcl2 deficiency, oligomeganephronia, mitotic catastrophe, cell competition, glomerular basement membrane, chronic kidney disease